44 Recruiting Studies Using Pertuzumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Pertuzumab
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
📍 Moffitt Cancer Center — Tampa, Florida
HER2-positive Breast Cancer
View Study & Checklist ➔Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
📍 Cedars Sinai Medical Center — Los Angeles, California
HER2-positive Breast Cancer
View Study & Checklist ➔A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
📍 Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul
Solid Tumors
View Study & Checklist ➔To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
📍 Massachusetts General Hospital. — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
📍 City of Hope Medical Center — Duarte, California
HER2 Positive Breast Carcinoma
View Study & Checklist ➔Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
📍 University of Alabama Comprehensive Cancer Center — Birmingham, Alabama
Breast Cancer
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
📍 Research Site — Springdale, Arkansas
Breast Neoplasms
View Study & Checklist ➔Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
📍 Massachusetts General Hospital — Boston, Massachusetts
HER-2 Positive Breast Cancer
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
📍 Highlands Oncology Group — Fayetteville, Arkansas
Advanced HER2+Breast Cancer
View Study & Checklist ➔Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
Breast Carcinoma
View Study & Checklist ➔CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist ➔A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
📍 Highlands Oncology Group - Duplicate 2 — Rogers, Arkansas
Breast Neoplasms
View Study & Checklist ➔Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
📍 UCSF — San Francisco, California
HER-2 Positive Breast Cancer
View Study & Checklist ➔A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
📍 Research Site — Fort Myers, Florida
Metastatic Breast Cancer
View Study & Checklist ➔DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
📍 Massachusetts General Hospital — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
📍 City of Hope National Medical Center — Duarte, California
Neoplasm Metastasis
View Study & Checklist ➔A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
📍 Stamford Hospital — Stamford, Connecticut
HER2-positive Breast Cancer
View Study & Checklist ➔A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
📍 Mayo Clinic Hospital — Phoenix, Arizona
HER2 Positive Breast Cancer
View Study & Checklist ➔A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Breast Cancer
View Study & Checklist ➔Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
📍 Houston Methodist Cancer Center — Houston, Texas
Breast Cancer
View Study & Checklist ➔Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Malignant Solid Neoplasm
View Study & Checklist ➔Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
📍 Research Site — Tucson, Arizona
Breast Cancer; HER2-positive; Metastatic
View Study & Checklist ➔MARGetuximab Or Trastuzumab (MARGOT)
📍 Georgetown University Medical Center — Washington D.C., District of Columbia
Breast Cancer
View Study & Checklist ➔Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
📍 Mount Sinai Beth Israel Comprehensive Cancer Center West — New York, New York
Breast Neoplasms
View Study & Checklist ➔Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
📍 University of California San Francisco — San Francisco, California
Brain Metastases
View Study & Checklist ➔Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
📍 Fox Chase Cancer Center — Philadelphia, Pennsylvania
HER2-positive Breast Cancer
View Study & Checklist ➔Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
📍 Moffitt Cancer Center — Tampa, Florida
HER2-positive Breast Cancer
View Study & Checklist ➔BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
📍 University of Illinois — Chicago, Illinois
Breast Cancer
View Study & Checklist ➔Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Anatomic Stage I Breast Cancer AJCC v8
View Study & Checklist ➔Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
📍 RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
HER2-positive Early-stage Breast Cancer
View Study & Checklist ➔I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Breast Neoplasms
View Study & Checklist ➔Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
📍 Hospital de Clínicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
Breast Cancer
View Study & Checklist ➔HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
📍 Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Breast Cancer
View Study & Checklist ➔Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
📍 Harris Health System - Smith Clinic — Houston, Texas
Breast Cancer
View Study & Checklist ➔The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Breast Cancer Female
View Study & Checklist ➔Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
📍 The University of Kansas Cancer Center (KUCC) — Fairway, Kansas
Breast Cancer
View Study & Checklist ➔A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
📍 Helios Clinical Research — Cerritos, California
HER2-positive Advanced Solid Tumor
View Study & Checklist ➔Elacestrant in Advanced Triple Positive Breast Cancer
📍 NYU Langone Health — New York, New York
ER Positive, HER2 Positive Breast Cancer
View Study & Checklist ➔Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
📍 M D Anderson Cancer Center — Houston, Texas
Anatomic Stage I Breast Cancer AJCC v8
View Study & Checklist ➔ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
📍 Cancer Center at Saint Joseph's — Phoenix, Arizona
Anatomic Stage I Breast Cancer AJCC v8
View Study & Checklist ➔A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
📍 Oncology Institute — Long Beach, California
HER2-positive Breast Cancer
View Study & Checklist ➔Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
📍 University of Colorado Anschutz Medical Campus ( Site 0057) — Aurora, Colorado
Breast Neoplasms
View Study & Checklist ➔